TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11815344

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (preservative-free)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 86
Study: 10188144

Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg daily
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg daily
Number of subjects: 247

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study: 7788827

Group type: EXPERIMENTAL
Intervention: alfentanil 0.03 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: alfentanil 0.015 mg.kg‐1 + esmolol 1 mg.kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: esmolol 2 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: saline
Number of subjects: 60
Study: 2146812

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin preparation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo preparation consisting of human serum albumin
Number of subjects: 12
Study: 672091

Group type: EXPERIMENTAL
Intervention: Cigarette smokers (n=28)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Non-smokers (n=30)
Number of subjects: 58
Study: 6810682

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30986785

Group type: EXPERIMENTAL
Intervention: Knowledge of stroke symptoms
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Perception of self-risk for stroke
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Gender perception of self-risk
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Preference for hospital care for stroke-like symptoms
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Association of hospital preference with socioeconomic status
Number of subjects: 670
Study: 28840324

Group type: COMPARATOR
Intervention: Mental rehearsal with a pre‐prepared checklist (Group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mental rehearsal with checklist and virtual models (Group B)
Number of subjects: 16
Study: 26595362

Group type: EXPERIMENTAL
Intervention: 0.5-mg conbercept
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 2.0-mg conbercept
Number of subjects: 53
Study: 24974440

Group type: EXPERIMENTAL
Intervention: Manual Muscle Strength Testing (MMST)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monofilament Testing (MFT)
Number of subjects: 30
Study: 22458336

Group type: EXPERIMENTAL
Intervention: Patient-centered advance care planning (PC-ACP)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 313
Study: 20375967

Group type: EXPERIMENTAL
Intervention: Soft silicone foam dressing (Mepilex Border)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Adhesive hydrocellular polyurethane foam dressing (Allevyn Adhesive)
Number of subjects: 32
Study: 17496674

Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (first variation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (second variation)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neuromonics Tinnitus Treatment (both variations)
Number of subjects: 35
Study: 15724760

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose (SM) adhesive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Single Bond (SB) adhesive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: One Coat Bond (OCB) adhesive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Overall restorations
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All adhesives
Number of subjects: 57
Study: 12140623

Group type: EXPERIMENTAL
Intervention: Alcohol (1.05 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9623685

Group type: EXPERIMENTAL
Intervention: SR 27417A (20 mg)
Number of subjects: 12
Study: 8124603

Group type: EXPERIMENTAL
Intervention: New drugs or novel drug combinations, new therapeutic modalities, or technological improvements of old modalities
Number of subjects: 0

Group type: COMPARATOR
Intervention: New therapies that represent modest, incremental advances over existing treatment
Number of subjects: 0
Study: 2643513

Group type: EXPERIMENTAL
Intervention: D-alpha-tocopheryl acetate (Vitamin E 400 IU/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 56650

Group type: EXPERIMENTAL
Intervention: Intravenous glycerol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intravenous dextrose
Number of subjects: 27
Study: 31606655

Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Digital droplet polymerase chain reaction (ddPCR)
Number of subjects: 135
Study: 28182498

Group type: EXPERIMENTAL
Intervention: ACTIVE training programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline cognitive performance
Number of subjects: 0
Study: 25818564

Group type: EXPERIMENTAL
Intervention: 2WAT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 4WAT
Number of subjects: 20

Group type: COMPARATOR
Intervention: CON
Number of subjects: 20
Study: 23835915

Group type: EXPERIMENTAL
Intervention: Endoscopic approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Microscopic approach
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of synechia presence
Number of subjects: 50
Study: 21350204

Group type: EXPERIMENTAL
Intervention: Preadmission warfarin use
Number of subjects: 1739
Study: 19266830

Group type: EXPERIMENTAL
Intervention: Midazolam 35 microg/kg administered intravenously 30 minutes before conclusion of surgery (Group MI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam 35 microg/kg premedication 15 minutes before induction of anesthesia (Group MP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 15 minutes before induction and 30 minutes before extubation (Group NS)
Number of subjects: 60
Study: 17920548

Group type: EXPERIMENTAL
Intervention: Blocking co‐stimulatory signals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking monoclonal antibodies
Number of subjects: 0
Study: 15564948

Group type: EXPERIMENTAL
Intervention: Gabapentin (titrated to 2,400 mg daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 41
Study: 11778528

Group type: EXPERIMENTAL
Intervention: Beclomethasone treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 23
Study: 8861661

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Grapefruit juice and erythromycin (CYP3A inhibitors)
Number of subjects: 0
Study: 1293307

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg daily for 2 weeks, then increased to 10 mg daily for 4 weeks if DBP was not < 90 mmHg or decreased by > 10 mmHg from baseline.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 11
Study: 6538006

Group type: EXPERIMENTAL
Intervention: gamma-vinyl GABA (1 g and 2 g daily for 2 weeks each)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo treatment (2 weeks)
Number of subjects: 10
Study: 31308344

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with HDM 300 IR tablets for 52 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 29474117

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) techniques training for healthcare providers
Number of subjects: 0
Study: 27174596

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fulvestrant plus a pan‐PI3K inhibitor
Number of subjects: 0
Study: 25566958

Group type: EXPERIMENTAL
Intervention: Dementia group (n = 86)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Non-dementia group (n = 958)
Number of subjects: 1044
Study: 23294513

Group type: EXPERIMENTAL
Intervention: Individual stress-management intervention (low-intensity followed by more intensive treatment if needed)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Individual stress-management intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 300
Study: 20497879

Group type: EXPERIMENTAL
Intervention: HA‐CMC solution (5 mL applied to the operative field after thyroidectomy)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no HA‐CMC solution)
Number of subjects: 74
Study: 18820783

Group type: EXPERIMENTAL
Intervention: Ventral cardiac denervation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 50
Study: 17243084

Group type: EXPERIMENTAL
Intervention: Daily physical activity of 45-60 minutes, fat-reduced diet with plenty of fruit, vegetables, whole grain, lean meat, and dairy products, moderate consumption of calorie-containing beverages.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing daily physical activity and regular exercise during the weight maintenance phase.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacement of starchy carbohydrates with protein from lean meat and dairy products.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dairy calcium consumption.
Number of subjects: 0
Study: 12811359

Group type: EXPERIMENTAL
Intervention: Pregabalin 186 mg daily
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Pregabalin (various doses: 0, 50, 150, 300, and 600 mg)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Pregabalin (various doses)
Number of subjects: 1042
Study: 11028738

Group type: EXPERIMENTAL
Intervention: Activated impulse stimulator
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inactivated impulse stimulator (non-stimulation group)
Number of subjects: 70
Study: 8707473

Group type: EXPERIMENTAL
Intervention: Passive tasks (sequence task and novel task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oddball task
Number of subjects: 0
Study: 1644129

Group type: EXPERIMENTAL
Intervention: Reciprocal command with opposing spring-like load (negative linear position feedback)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coactivation command with assisting load (positive position feedback)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No load condition after training with opposing or assisting loads
Number of subjects: 0
Study: 6548428

Group type: EXPERIMENTAL
Intervention: Chlorpropamide alcohol flushing (CPAF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Forearm ischaemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of plasma levels of 6-oxo-PGF1 alpha and TXB2
Number of subjects: 0
Study: 30448936

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (14 kcal kg-1 body weight weekly)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Moderate-intensity aerobic exercise (8 kcal kg-1 body weight weekly)
Number of subjects: 49
Study: 29287665

Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Referral to a telephone quitline
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Texting program
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1056
Study: 27437769

Group type: EXPERIMENTAL
Intervention: 6-gene risk score based on expression of ABCC4, ADRBK2, KLHL23, PDS5A, UHRF1, ZNF551
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Risk score from merged public datasets
Number of subjects: 96
Study: 25183042

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 654

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 654
Study: 21939613

Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg/d
Number of subjects: 221

Group type: COMPARATOR
Intervention: Aripiprazole 2 mg/d
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 20643486

Group type: EXPERIMENTAL
Intervention: Left rTMS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Right rTMS
Number of subjects: 48

Group type: COMPARATOR
Intervention: Left sham
Number of subjects: 48

Group type: COMPARATOR
Intervention: Right sham
Number of subjects: 48
Study: 17764782

Group type: EXPERIMENTAL
Intervention: Octreotide 75 microg subcutaneously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% normal saline solution subcutaneously)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment (1 ampule of 50% dextrose intravenously and carbohydrates orally) + Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Standard treatment (1 ampule of 50% dextrose intravenously and carbohydrates orally) + Octreotide
Number of subjects: 40
Study: 15809460

Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 810

Group type: COMPARATOR
Intervention: Repeated ultrasonography
Number of subjects: 810
Study: 12748877

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies in epileptic patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies in epileptic patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Glutamic acid decarboxylase antibodies in epileptic patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Anticardiolipin antibodies in seizure-free patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Glutamic acid decarboxylase antibodies in seizure-free patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Antinuclear antibodies in well-controlled epilepsy
Number of subjects: 74
Study: 10234587

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) measurements at multiple bone sites including calcaneus, distal third and ultradistal radius, proximal third phalanx, metacarpal, capitate, patella, and posterior process of the thoracic spine.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Distal radius and calcaneus measurements.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combined assessment at two sites (calcaneus and distal radius).
Number of subjects: 79
Study: 7914238

Group type: EXPERIMENTAL
Intervention: Vitamin E (600 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3551850

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29608976

Group type: EXPERIMENTAL
Intervention: Respiratory muscle stretching
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (at rest)
Number of subjects: 10
Study: 27716091

Group type: EXPERIMENTAL
Intervention: DWL‐FWSC (Durable Wall Lining - Full Wall Surface Coverage)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: DWL‐RWSC (Durable Wall Lining - Reduced Wall Surface Coverage)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 146
Study: 26232169

Group type: EXPERIMENTAL
Intervention: Low fat/high carbohydrate meal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saturated fatty acids (SFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polyunsaturated fatty acids (PUFA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gender comparison (women vs men)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meal × time interaction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plasma D-dimer, interleukin-6, interleukin-1β, tumor necrosis factor-α, high sensitivity C-reactive protein
Number of subjects: 30
Study: 23925740

Group type: EXPERIMENTAL
Intervention: Cementless unicompartmental knee replacement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cemented unicompartmental knee replacement
Number of subjects: 62
Study: 21743067

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) anaesthesia
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-pharmacological methods of pain relief
Number of subjects: 70
Study: 19404671

Group type: EXPERIMENTAL
Intervention: Calisthenic training (CT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 16
Study: 16688841

Group type: EXPERIMENTAL
Intervention: Parenteral or enteral nutrition (24.6±5.2 kcal/kg per day non-protein and 0.23±0.04 g nitrogen/kg per day)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group (600±100 kcal non-protein plus or not plus 62±16 g crystalline amino acids postoperatively)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Nutrition group
Number of subjects: 468
Study: 15474852

Group type: EXPERIMENTAL
Intervention: Anxious participants watching a video of an actor portraying anxious affect
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Dysphoric participants watching a video of an actor portraying depressed affect
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control participants watching a video of an actor portraying neutral affect
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All participants (anxious, dysphoric, and control) watching a video of an actor portraying depressed affect
Number of subjects: 208
Study: 11770696

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension 0.25 mg, 0.5 mg, or 1.0 mg once daily for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (0.25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9792256

Group type: EXPERIMENTAL
Intervention: Positive polymerase chain reaction tests for C. pneumoniae
Number of subjects: 282
Study: 7973476

Group type: EXPERIMENTAL
Intervention: Progressive dynamic strength training (EG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 39
Study: 2638954

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine mouthwash
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 14
Study: 30321909

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Galcanezumab (4 doses)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 28028318

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone undecanoate (n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n=51)
Number of subjects: 100
Study: 25597607

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy (PP) performed on patients in Group A.
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (no posterior pericardiotomy) in Group B.
Number of subjects: 207
Study: 23363466

Group type: EXPERIMENTAL
Intervention: Email prompt after 2 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Email prompt after 4 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Email prompt after 6 weeks
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Email prompt with additional content
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no additional email prompt)
Number of subjects: 240
Study: 21912927

Group type: EXPERIMENTAL
Intervention: Tracking training in the morning
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tracking training in the evening
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sleep following training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cortical excitability measures
Number of subjects: 40
Study: 19463300

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 310
Study: 16490804

Group type: EXPERIMENTAL
Intervention: 6 tablets of erlotinib 25 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 1 tablet of erlotinib 150 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: 25 mg intravenous infusion of erlotinib
Number of subjects: 62
Study: 12620563

Group type: EXPERIMENTAL
Intervention: Surgical oncology fellowship (SO)
Number of subjects: 201

Group type: COMPARATOR
Intervention: General surgery training (GS)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Other fellowships (OF)
Number of subjects: 201
Study: 11073286

Group type: EXPERIMENTAL
Intervention: Closerin capsules (250 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dura seromycin capsules (250 mg)
Number of subjects: 24
Study: 9196315

Group type: EXPERIMENTAL
Intervention: Heparin coated cardiopulmonary bypass (n = 56)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 120
Study: 8446653

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 21
Study: 3536389

Group type: EXPERIMENTAL
Intervention: Phosphate enemas
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sorbit enemas
Number of subjects: 60
Study: 29422475

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) (EQUIA; GC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Microhybrid resin composite (Amelogen Plus; Ultradent)
Number of subjects: 40
Study: 26482398

Group type: EXPERIMENTAL
Intervention: Voice education program for 4 weeks followed by 4 weeks of continued practice
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 127
Study: 24488359

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional localization
Number of subjects: 20
Study: 23027068

Group type: EXPERIMENTAL
Intervention: Land-based home exercise programme (n = 43), 12 weeks, 4 days per week at the hospital
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (n = 38), waiting list
Number of subjects: 81
Study: 19423094

Group type: EXPERIMENTAL
Intervention: Electroejaculation or penile vibrating stimulation semen cryopreservation using a commercial TEST‐yolk‐buffer technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (men without spinal cord injury)
Number of subjects: 0
Study: 18534880

Group type: EXPERIMENTAL
Intervention: Conventional full-time patching
Number of subjects: 57

Group type: COMPARATOR
Intervention: Atropine penalization
Number of subjects: 57
Study: 15951468

Group type: EXPERIMENTAL
Intervention: Everolimus (0.75-10 mg/d) for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12477672

Group type: EXPERIMENTAL
Intervention: PCA containing 20 mg tramadol + 1 mg metoclopramide per millilitre (Group T+M)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCA containing 20 mg tramadol (Group T)
Number of subjects: 40